Therapeutic angiogenesis, stimulated growth of new vasculature to compensate for tissue ischemia, remains an unfulfilled promise. After nearly a decade of trials, the development of drugs capable of stimulating revascularization of underperfused tissues remains an exciting but unrealized goal in cardiovascular therapeutics. This review will summarize experiences in therapeutic angiogenesis stud...

Angiogenesis inhibition has been proposed as a general strategy to fight cancer. However, in spite of the promising preclinical results, a first generation of antiangiogenic compounds yielded poor results in clinical trials. Conceptual errors and mistakes in the design of trials and in the definition of clinical end-points could account for these negative results. In this context of discouragin...

Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy ...

Coronary artery disease, ischemic cardiomyopathy, and congestive heart failure continue to confer significant morbidity and mortality despite advances in medical therapy, percutaneous coronary interventions, and surgical revascularization.1,2 This unmet clinical need is the rationale for novel therapeutic strategies like therapeutic angiogenesis. Unlike traditional revascularization, which focu...

Although traditional Chinese medicine is effective and safe for the treatment of angiogenesis, in vivo intervention mechanism diverse, complex, largely unknown. Therefore, we aimed to explore active ingredients their mechanisms action against angiogenesis. Data on angiogenesis-related targets were collected from GeneCards, Therapeutic Target Database, Online Mendelian Inheritance Man, DrugBank,...

Genetic medicines that induce angiogenesis represent a promising strategy for the treatment of ischemic diseases. Many types of nonviral delivery systems have been tested as therapeutic angiogenesis agents. However, their delivery efficiency, and consequently therapeutic efficacy, remains to be further improved, as few of these technologies are being used in clinical applications. This article ...

Targeting angiogenesis is considered a promising therapy for cancer. Besides curtailing soluble factor mediated tumor angiogenesis, understanding the unexplored regulation of angiogenesis by mechanical cues may lead to the identification of novel therapeutic targets. We have recently shown that expression and activity of mechanosensitive ion channel transient receptor potential vanilloid 4 (TRP...

Fragments from the extracellular matrix proteins laminin and osteopontin and a sequence from VEGF have potent proangiogenic activity despite their small size (< 10 residues). However, these linear peptides have limited potential as drug candidates for therapeutic angiogenesis because of their poor stability. In the present study, we show that the therapeutic potential of these peptides can be s...

Angiogenesis is disregulated in many diseased states, most notably in cancer. An emerging strategy for the development of therapies targeting tumor-associated angiogenesis is to harness the potential of nanotechnology to improve the pharmacology of chemotherapeutics, including anti-angiogenic agents. Nanoparticles confer several advantages over that of free drugs, including their capability to ...

............................................................................................................................ 6 REVIEW OF THE LITERATURE...................................................................................... 7 1. THE BLOOD VASCULAR SYSTEM........................................................................... 7 Development of the blood vessels......................